Database Member Home
RAS Member Home
Building and maintaining effective Key Opinion Leader (KOL) relationships can help drive successful development and commercialization of biopharmaceutical drugs and medical devices. In wake of an increasingly restricted and competitive environment, biopharmaceutical companies must optimize their KOL management structure and responsibility. The best organizational structures for KOL management must align with scientific as well as commercial perspectives.
This video provides inputs on the organizational responsibility for thought leader management, optimal structure for managing Key Opinion Leaders, transparency in engaging with KOLs and the role of Medical Affairs in Key Opinion Leader management.
This video will provide important benchmarks around the responsibility and optimal organizational structure for Thought Leader management.
Pharmaceutical companies continue to improve the effectiveness of their managed care interactions by employing specialized medical liaisons who can speak the "payer language... (ID POP-283)
Read More »
In pharma, regulatory and access restrictions have reshaped key interactions with thought leaders... (ID POP-267)
Key Opinion Leaders (KOLs) are recognized as one of the most effective avenues for building awareness in medical and scientific communities... (ID POP-253)
Pharmaceutical and life science companies rely heavily on key opinion leaders (KOLs) to improve their credibility in the marketplace... (ID PSM-235)
Pharmaceutical and medical device organizations seek strategic insights and guidance to successfully navigate the complexities of the changing healthcare landscape... (ID PSM-319)
As Medical Science Liaisons (MSLs) increasingly face restricted access to physicians and KOLs, it is important for biopharmaceutical and medical device companies to empower MSLs with new processes and tools that facilitate rapid and effective customer engagement... (ID POP-286)